KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.

R J Motzer, C Porta, M Eto, T E Hutson, S Y Rha, J R Merchan, E Winquist, H Gurney, V Grünwald, S George, J Markensohn, J E Burgents, R Cristescu, P Sachdev, Y Narita, J Huang, Z Zhao, C E Okpara, Y Minoshima, T K Choueiri

Ann Oncol 36(4) 375-386

PMID39672382
PMCIDPMC12459081
DOI10.1016/j.annonc.2024.12.003
发表日期2024-12-13
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: In CLEAR, lenvatinib + pembrolizumab (L + P) significantly improved efficacy versus sunitinib in first-line treatment of patients with advanced renal cell carcinoma (aRCC). We report results from CLEAR biomarker analyses. PATIENTS AND METHODS: Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) and next-generation sequencing assays (whole exome sequencing/RNA sequencing) were carried out on archival tumor specimens. For IHC-derived/RNA sequencing analyses, a continuous analysis was carried out adjusting by Karnofsky performance status (KPS) score for: PD-L1 combined positive score (CPS) versus best overall response (BOR)/progression-free survival (PFS); and each gene signature score [T-cell inflamed gene expression profile (TcellinfGEP)/non-TcellinfGEP signatures including proliferation and angiogenesis] versus BOR/PFS. Association between mutation status of RCC driver genes and PFS were analyzed for genes for which ≥20 patients per arm had oncogenic alterations. Association of molecular subtypes with outcome was evaluated with baseline KPS adjustments. The set of biomarkers evaluated and statistical significance criteria for PD-L1 CPS, gene signature scores, and molecular subtypes were prespecified. RESULTS: Within-arm analyses using continuous values showed no association between PD-L1 levels and BOR/PFS for either treatment. PFS hazard ratios between arms were similar regardless of the mutant or wild-type subgroups of RCC driver genes (VHL, PBRM1, SETD2, BAP1, KDM5C). No associations between PFS and gene signature scores were observed for L + P. With sunitinib, high proliferation and MYC signature scores showed shorter PFS; high angiogenesis and microvessel density signature scores showed longer PFS. Six new molecular subtypes were defined. Tumors of patients with favorable/intermediate risk were enriched in angiogenesis and angiogenesis/stromal clusters; those with poor risk were enriched in proliferative and unclassified (low-TcellinfGEP/low-angiogenesis/low-proliferation) clusters. No association between molecular subtypes and PFS for L + P/sunitinib was observed (after adjustment for KPS and gene signatures that were individually associated with PFS). CONCLUSIONS: Improvements in objective response rate and PFS for L + P versus sunitinib in aRCC were observed consistently across a range of biomarker subgroups defined using RCC driver mutations, PD-L1, gene expression signatures, and molecular subtypes.

KM 提取结果

1 个 Figure · 10 个 KM 面板

进入结果中心
KM Figure10 个面板

Figure 3.

Analyses of gene signature scores. A) Within-arm association analysis of continuous gene signature scores by BOR, and B) between-arm association analysis of gene signature scores by PFS for signature-high and -low subgroups separately; C) Kaplan-Meier curves of PFS between arms for signature-high and -low subgroups separately. Cutoff values (1st tertile of Tcell inf GEP, median of non-Tcell inf GEP signatures) were determined based on the combined three arms. High/non-low: >= cutoff; low: <cutoff. For figure 3A , P -values in the boxplots were for within-arm testing and were calculated using logistic regression adjusted by KPS, one-sided and nominal for Tcell inf GEP in the L+P arm, two-sided and nominal for Tcell inf GEP in the S arm, and two-sided and BH FDR adjusted for non-Tcell inf GEP signatures. Angio36, angiogenic & growth factor pathway; BOR, best overall response; BH, Benjamini Hochberg; CI, confidence interval; EMT, epithelial-mesenchymal transition; FDR, false discovery rate; HR, hazard ratio; KPS, Karnofsky performance status; L+P, lenvatinib plus pembrolizumab; m/gMDSC, monocytic/granulocytic myeloid-derived suppressor cells; MVD, microvessel density; PFS, progression-free survival; S, sunitinib; Tcell inf GEP, T-cell inflamed gene expression profile.

Angiogenesis_-_Low

PFS

Figure 3. · Panel Angiogenesis_-_Low

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Angiogenesis_-_Low 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
MVD_-_Low

PFS

Figure 3. · Panel MVD_-_Low

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel MVD_-_Low 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Proliferation_-_Low

PFS

Figure 3. · Panel Proliferation_-_Low

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Proliferation_-_Low 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
MYC_-_Low

PFS

Figure 3. · Panel MYC_-_Low

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel MYC_-_Low 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 2:extreme jump
查看结果
GEP_-_Low

PFS

Figure 3. · Panel GEP_-_Low

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel GEP_-_Low 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Angiogenesis_-_High

PFS

Figure 3. · Panel Angiogenesis_-_High

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Angiogenesis_-_High 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
MVD_-_High

PFS

Figure 3. · Panel MVD_-_High

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel MVD_-_High 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Proliferation_-_High

PFS

Figure 3. · Panel Proliferation_-_High

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Proliferation_-_High 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:off origin start
查看结果
MYC_-_High

PFS

Figure 3. · Panel MYC_-_High

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel MYC_-_High 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:off origin start
查看结果
GEP_-_High

PFS

Figure 3. · Panel GEP_-_High

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel GEP_-_High 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Baseline mutation rates and ORR by mutational status of RCC driver genes. A) Mutational landscape in the lenvatinib plus pembrolizumab and sunitinib arms; B) ORR in mutant and wildtype subgroups for select mutations (≥20 mutants per arm). Oncogenic mutations were annotated by OncoKB platform. Please see further details regarding this analysis under “ Methods ” of the Supplementary Appendix . CI, confidence interval; KPS, Karnofsky performance status; L+P, lenvatinib plus pembrolizumab; Mut, mutant; ORR, objective response rate; RCC; renal cell carcinoma; S, sunitinib; WT, wildtype.
非 KM Figure
Figure 2.Between-arm PFS analysis by mutational status of RCC driver genes. A) Kaplan-Meier curves of PFS between arms for mutant and wildtype subgroups of RCC driver genes, and B) further PFS analysis of RCC driver gene mutation status between arms. *Interpretation is limited by small sample size. For Figure 2B , evaluations were by Cox regression model (adjusted by KPS) between arms in Mut and WT subgroups, separately. CI, confidence interval; HR, hazard ratio; KPS, Karnofsky performance status; L+P, lenvatinib plus pembrolizumab; Mut, mutant; PFS, progression-free survival; RCC, renal cell carcinoma; S, sunitinib; Strat, stratification; WT, wildtype.
非 KM Figure
Figure 4.Distribution and analyses of molecular subtypes. A) Distribution of molecular subtypes across MSKCC risk categories and PD-L1 subgroups (CPS≥1 as PD-L1+ and CPS<1 as PD-L1-). Analysis of B) ORR and C) PFS by molecular subtypes in the lenvatinib plus pembrolizumab and sunitinib arms. The “unclassified” cluster was defined as low- Tcell inf GEP/low-angiogenesis/low-proliferation ( Supplementary Figure S2 ). *Associations between molecular subtypes and PFS were tested by a 5-degree of freedom likelihood ratio test (while adjusting for KPS). An association between PFS and the S arm ( P =0.0009) was further evaluated by adding signatures (associated significantly with KPS-adjusted PFS; including proliferation, MYC, angiogenesis and microvessel density) as covariates to test the independent value of the molecular subtypes. Molecular subtypes were associated with PFS in the S arm but not after adjustment for KPS and gene signatures that were shown to individually associate with PFS in the S arm (Pr[>Chisq]=0.1721). CPS, combined positive score; IHC, immunohistochemistry; KPS, Karnofsky performance status; L+P, lenvatinib plus pembrolizumab; MSKCC, Memorial Sloan Kettering Cancer Center; NE, not estimable; ORR, objective response rate; PD-L1, programmed death ligand 1; PFS, progression-free survival; S, sunitinib; Tcell inf GEP, T-cell inflamed gene expression profile.
非 KM Figure